Arena favors discretion over valor with Belviq in EU
This article was originally published in Scrip
Executive Summary
Arena Pharmaceuticals has withdrawn its EU marketing application for Belviq (lorcaserin HCl) with a view to a later refiling, in the latest regulatory hiccup for the new wave of obesity treatments. The markets were not impressed, sending Arena's share price down to $8.21 during trading on Nasdaq on 2 May, but it later rallied to close up by 2.1% at $8.40.